Gene Therapy Market Size, Share, And Trends - Global Forecast 2026-2032 28.80% CAGR To Propel Market To USD 75.92 Billion As AI And Gene Editing Unlock Growth


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Maximize gene therapy ROI through scalable manufacturing, AI-enabled development, durable evidence, outcomes-based reimbursement and strategic access partnerships.

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Gene Therapy Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The Gene Therapy Market research report examines an industry projected to reach USD 16.35 billion in 2026 and expand at a CAGR of 28.80% to USD 75.92 billion by 2032. It assesses clinical validation, technology platforms, manufacturing constraints, commercialization models, and regional opportunities across rare diseases, oncology, hematology, ophthalmology, neurology, and inherited metabolic disorders.

Market Growth and Commercial Dynamics

Gene therapy is progressing from specialized research into an established treatment model, supported by approved in vivo and ex vivo therapies using adeno-associated virus (AAV), lentiviral vectors, CAR-T platforms, and genome editing. Regulatory approvals for retinal dystrophy, spinal muscular atrophy, hematologic cancers, sickle cell disease, and transfusion-dependent beta thalassemia have reinforced confidence in long-term therapeutic potential.

  • Growth drivers include unmet medical need, higher genetic diagnosis rates, orphan drug incentives, expanded newborn screening, and broader clinical pipelines.
  • Commercialization challenges include specialized manufacturing, cold-chain logistics, safety monitoring, long-term follow-up, and value-based reimbursement.
  • Organizations integrating clinical evidence, scalable production, regulatory alignment, and patient access strategies are best positioned to compete.

The analysis supports strategic planning by clarifying where clinical momentum, infrastructure readiness, and reimbursement innovation are creating viable market opportunities.

Transformative Industry Shifts

Development is shifting from single-product breakthroughs toward reusable platforms built on validated vectors, modular manufacturing, and disease-area expertise. Manufacturing capacity has become a major differentiator as vector supply, potency assays, quality controls, yield variability, and cost of goods affect launch readiness.

Non-viral delivery, lipid nanoparticles, improved capsid engineering, base editing, prime editing, and targeted in vivo delivery are broadening the competitive landscape. Meanwhile, outcomes-based agreements, installment payments, patient registries, and real-world evidence are becoming central to market access for high-cost, one-time therapies.

Artificial Intelligence Across the Value Chain

Artificial intelligence is improving target identification, vector engineering, sequence optimization, patient stratification, and trial design. In manufacturing, predictive analytics can support process monitoring, assay optimization, deviation detection, and batch-failure reduction. AI is also strengthening adverse-event surveillance and long-term follow-up analytics.

These insights enable decision-makers to prioritize technology investments, manage development risk, and evaluate competitors with stronger data and manufacturing capabilities.

Regional and Strategic Market Insights

  • North America: Leads through biotechnology financing, regulatory experience, clinical trials, specialist centers, advocacy networks, and manufacturing capacity.
  • Europe: Benefits from the advanced therapy medicinal products framework and strong clinical infrastructure, although country-level pricing and health technology assessments can delay access.
  • Asia-Pacific: Expands through investment in genomic medicine, domestic manufacturing, and clinical research, particularly in China, Japan, South Korea, India, and Australia.
  • Latin America: Brazil and Mexico offer developing clinical and regulatory capacity, while affordability and diagnostic access remain barriers.
  • Middle East and Africa: GCC markets are investing in precision medicine and genomic screening, while African opportunities center on diagnostics, newborn screening, and inherited blood disorders.

ASEAN offers growth through improving hospitals, genetic testing, and medical tourism, while the GCC benefits from centralized healthcare investment. G7 markets remain dominant in approvals and reimbursement innovation; BRICS markets provide long-term potential based on population scale and expanding biotechnology investment. Regional comparisons inform market entry strategies by identifying differences in regulation, financing, treatment-center capacity, and patient access.

Strategic Priorities for Industry Leaders

  • Build scalable manufacturing, validated potency assays, robust quality systems, and dual sourcing into early development.
  • Align clinical endpoints with payer expectations for durable patient outcomes.
  • Develop registries and real-world evidence programs supporting long-term monitoring.
  • Evaluate outcomes-based reimbursement, staged payments, and risk-sharing agreements.
  • Expand genetic testing partnerships, patient identification, and centers-of-excellence networks.
  • Form alliances with academic institutions, manufacturers, diagnostics providers, patient organizations, and regional health systems.

Key Takeaways from This Report

  • The market is forecast to reach USD 75.92 billion by 2032.
  • Platform development, next-generation delivery, and AI are reshaping competition.
  • Manufacturing quality and scalability remain critical commercial differentiators.
  • Durable evidence and innovative reimbursement models are essential for patient access.
  • Regional success depends on regulatory maturity, diagnostic capacity, financing, and specialized treatment infrastructure.

Key Attributes:

Report Attribute Details
No. of Pages 195
Forecast Period 2026 - 2032
Estimated Market Value (USD) in 2026 $16.35 Billion
Forecasted Market Value (USD) by 2032 $75.92 Billion
Compound Annual Growth Rate 28.8%
Regions Covered Global


Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Gene Therapy Market, by Vector Type
7.1. Introduction
7.2. Non-Viral Vectors
7.2.1. Lipofection
7.2.2. Plasmid DNA
7.3. Viral Vectors
7.3.1. Adeno-Associated Virus (AAV) Vectors
7.3.2. Adenovirus Vectors
7.3.3. Herpes Simplex Virus (HSV) Vectors
7.3.4. Retrovirus Vectors
8. Gene Therapy Market, by Therapy Type
8.1. Introduction
8.2. Gene Replacement Therapy
8.3. Gene Silencing Therapy
8.4. Gene Editing Therapy
8.5. Gene Augmentation Therapy
8.6. Cell-Based Gene Therapy
9. Gene Therapy Market, by Target Genome
9.1. Introduction
9.2. DNA Modification
9.3. RNA Modification
10. Gene Therapy Market, by Delivery Mode
10.1. Introduction
10.2. Ex Vivo
10.3. In Vivo
11. Gene Therapy Market, by Route of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intraocular
11.4. Intravenous
12. Gene Therapy Market, by Patient Type
12.1. Introduction
12.2. Adult Patients
12.3. Pediatric Patients
13. Gene Therapy Market, by Therapeutic Area
13.1. Introduction
13.2. Cardiovascular Diseases
13.2.1. Coronary Artery Disease
13.2.2. Heart Failure
13.3. Infectious Diseases
13.3.1. Hepatitis B
13.3.2. HIV
13.4. Monogenic Disorders
13.4.1. Cystic Fibrosis
13.4.2. Hemophilia
13.4.3. Sickle Cell Anemia
13.5. Oncological Disorders
13.5.1. Hematological Malignancies
13.5.2. Solid Tumors
14. Gene Therapy Market, by End-User
14.1. Introduction
14.2. Contract Research Organizations
14.3. Hospitals & Clinics
14.4. Pharmaceutical & Biotech Companies
14.5. Research Institutes
15. Gene Therapy Market, by Region
15.1. Introduction
15.2. Asia-Pacific
15.3. North America
15.4. Latin America
15.5. Europe
15.6. Middle East
15.7. Africa
16. Gene Therapy Market, by Group
16.1. Introduction
16.2. ASEAN
16.3. GCC
16.4. European Union
16.5. BRICS
16.6. G7
16.7. NATO
17. Gene Therapy Market, by Country
17.1. Introduction
17.2. United States
17.3. China
17.4. Germany
17.5. United Kingdom
17.6. Japan
17.7. India
17.8. France
17.9. Canada
17.10. Brazil
17.11. Australia
17.12. Spain
17.13. Italy
17.14. Russia
17.15. Mexico
17.16. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. Market Concentration Analysis, 2025
18.2.1. Concentration Ratio (CR)
18.2.2. Herfindahl Hirschman Index (HHI)
18.3. Recent Developments & Impact Analysis, 2025
18.4. Product Portfolio Analysis, 2025
18.5. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Abeona Therapeutics Inc.
19.2. Adaptimmune Therapeutics PLC
19.3. Adverum Biotechnologies, Inc.
19.4. AGC Biologics
19.5. Alnylam Pharmaceuticals, Inc.
19.6. American Gene Technologies Inc.
19.7. Amgen Inc.
19.8. AnGes, Inc.
19.9. Astellas Pharma Inc.
19.10. Biogen Inc.
19.11. bluebird bio, Inc.
19.12. Cellectis S.A.
19.13. CRISPR Therapeutics AG
19.14. Danaher Corporation
19.15. Editas Medicine, Inc.
19.16. F. Hoffmann-La Roche Ltd.
19.17. Gilead Sciences, Inc.
19.18. Intellia Therapeutics
19.19. Ionis Pharmaceuticals, Inc.
19.20. Johnson & Johnson
19.21. Merck KGaA
19.22. Mustang Bio, Inc.
19.23. Novartis AG
19.24. Orchard Therapeutics PLC
19.25. Poseida Therapeutics, Inc.
19.26. Sangamo Therapeutics, Inc.
19.27. Sarepta Therapeutics, Inc.
19.28. Sibiono GeneTech Co. Ltd.
19.29. Syncona Limited
19.30. ViGeneron GmbH
19.31. Voyager Therapeutics Inc.
20. Key Experts

List of Figures [27]
List of Tables [373]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112026004107003653ID1111990336


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search